American Health Intel Rules. Money. Medicine. Decoded daily.
Subscribe
The Service Line · Sunday, November 15, 2026

The Service Line

Rules. Money. Medicine. Decoded daily.
5 stories · 6 min read
Reading as

Medicare did not hand independents a lifeline this week. It handed the advantage to whoever is already inside. All six Service Line deep dives ran, from primary care on Monday to surgery centers on Saturday, and the thread running through them is that the 2027 Medicare finals, the home health and hospice enrollment freeze and the biggest surgery center deal of the year all reward incumbents. Below are the five items a cross-specialty operator must not have missed, each re-checked against a source this run where we could, plus one connective insight. Confidence: High on the dates and figures we re-verified, tiers stated per item otherwise.

Every Medicare-billing specialty: the conversion factor is $32.63, and being inside an ACO is now worth 16 points on the visit

The 2027 non-qualifying conversion factor, the dollar multiplier on every relative value unit, is $32.63, a 2.31 percent cut from $33.40, and $32.95 for clinicians in a qualifying advanced payment model, per Fierce Healthcare’s final rule report and the American College of Cardiology summary. Outlets disagree on the qualifying-model percentage (1.83 or 1.86), so confirm against the CMS fact sheet before you publish a figure. In primary care, the G2211 complexity add-on code is replaced by modifier B1, worth 16 percent on the visit, and modifier B2, worth 32 percent for clinicians in the Medicare Shared Savings Program or the LEAD Model, per CMS. Accountable care organizations (ACOs) that applied for a January 1 start have until noon Eastern Tuesday, November 17, to revise their track election. Reprice surgeon pay and payer contracts on $32.63, and decide this week whether your primary care physicians belong in a model. Confidence: High on the conversion factor and modifier structure; Medium on the dollar value per visit, our approximation from Monday’s issue.

Hospital clinics and surgery centers: 340B drugs drop to average sales price minus 28 percent, and the surgery center payment weight falls to 0.814

In the final outpatient rule, hospital cancer clinics will be paid average sales price minus 28 percent for drugs bought through the 340B discount program from January 1, against 33.4 percent proposed, per the CMS final rule fact sheet as read in Wednesday’s issue. On a drug with a $10,000 average sales price, that is $7,200 instead of $10,600, our arithmetic. The same rule gives surgery centers a 2.3 percent update, but ASC News reports the payment weight scalar falls from 0.872 to 0.814 and that the Ambulatory Surgery Center Association says 85 of the top 100 procedures by Medicare volume decline. The headline and your own rate can differ in sign, so run your top 10 codes by volume against the addenda. Confidence: Medium. We did not re-open the rule or its addenda this run; the 340B rate and scalar come from Wednesday’s and Saturday’s issues.

Home health and hospice: the freeze is extended six more months, and incumbents may now add locations

CMS announced November 12 that it will extend the nationwide moratoria on new Medicare hospice and home health agency enrollment for another six months, per the CMS press release, which we read this run. Unlike May, the extension lets currently enrolled agencies add practice locations under their existing enrollment, while new initial applications and certain majority-ownership changes stay blocked. The release gives no end date; the accrediting body CHAP reports May 12, 2027, which we did not confirm in the Federal Register. Last Sunday we told you to plan for both outcomes, and this is the first one. The same release says a two-day October California site-visit sweep produced 145 revocations tied to more than $703 million in payments, and the 2027 final rule lets revocations reach back to the date of noncompliance. Confidence: High on the extension, the location change and the California figures (CMS); Medium on the end date.

Surgery centers: a $6 billion deal got a higher price and a rejected rival bid at $28

Surgery Partners and HealthSpan Partners, an affiliate of the nonprofit system Bon Secours Mercy Health, amended their merger to $25.00 per share in cash, about $6.0 billion, up from $23.50 and $5.7 billion, per the company’s 8-K exhibit as summarized in search results this run. Stockholders other than Bain Capital, which holds about 39 percent and rolls its shares over, get a ticking fee of up to $1.61 per share if closing slips, and a third party’s nonbinding $28.00 offer was judged not a superior proposal. Healthcare Finance News reports, citing Bloomberg, that the bidder was UnitedHealth Group, which neither company has confirmed. Closing is still targeted for the first quarter of 2027, subject to stockholder and regulatory approval. Community Health Systems’ chief executive also said Tuesday it will lean “a little heavier” into surgery centers. For surgeon-owners, health systems and insurers are the bidders, and who is buying shapes the outcome as much as the price. Confidence: High on the terms; Low on the rival’s identity.

Behavioral health and telehealth prescribers: the DEA rule is still at the White House, and December 31 is 46 days out

The Drug Enforcement Administration’s final rule on special registrations for telemedicine prescribing of controlled substances has been at the White House Office of Information and Regulatory Affairs since August 25, with stakeholder meetings continuing into November, per Frier Levitt’s tracker and the OIRA record cited in Thursday’s issue. No rule text is public, and we found no published final rule or extension this run. The current prescribing flexibilities expire December 31, 2026, and the standard 90-day review window would end around late November, with one possible 30-day extension. Any virtual-first psychiatry or stimulant program needs a written Plan B for January 1, and should watch the Federal Register this week. Confidence: High that the rule is pending; Low on whether it publishes before the cliff or whether another extension follows.

Also on the watch list

The Fifth Circuit has not ruled on the Medicare Advantage audit extrapolation case argued October 5, where STAT reported the panel seemed poised to toss the rule again, and we found no decision this run. Cencora’s roughly $2.4 billion bid for American Oncology Network has no confirmed close date, and the PROGRESS valve trial in moderate aortic stenosis cut death or heart failure events to 16.7 percent from 23.9 percent with similar mortality. Confidence: High that no ruling has issued, per our search.

Connective tissue: the 2027 rules pay for being inside, and the buyers are the ones already inside

Read the week as one pattern. Primary care gets a 16-point premium for sitting inside an accountable care model. Home health and hospice incumbents may add locations while newcomers are frozen out. Hospital outpatient drug margins on 340B shrink, but the buyers circling surgery centers, a nonprofit system, an insurer, a hospital chain and a drug distributor, are exactly the large organizations that can absorb a lower scalar. Independent operators face a squeeze from both sides: lower base rates and higher entry barriers, with scale as the offered way out. The practical move is to price your own optionality now, either a documented path into a model or a clear read on what a strategic buyer would pay, before January 1 resets the rates. Confidence: Medium, our synthesis of the sourced items above, not a sourced finding.

This Week’s Operator Metrics, At a Glance

  • Primary care and accountable care: about $14 per qualifying 99214 visit, the B2 versus B1 gap, our arithmetic from Monday’s issue (approximate base rate).
  • Cardiology: $293.66, the 2027 work-component payment for left atrial appendage closure (33340), our arithmetic at $32.6286 as read Tuesday.
  • Oncology: $3,400 swing per $10,000 drug in 340B hospital payment, our arithmetic.
  • Behavioral health: 14 of 28 traditional deals in Q3 were sponsor-backed add-ons, per Mertz Taggart as read Thursday.
  • Home health and hospice: 108.8 days, Addus’s Q3 hospice average length of stay, up from 89.6, per its SEC exhibit as read Friday.
  • Surgery and ASCs: 0.814, the 2027 payment weight scalar, down from 0.872, per ASC News.

Get tomorrow's edition in your inbox.

Free. One email a day at 6pm your time, or one summary every Friday. Switch or stop anytime.

Where these stories are tracked
2027 physician fee schedule sets $32.63 conversion factor and ACO visit modifiers Rule tracked on Rule tracker Open →
340B drugs drop to ASP minus 28 percent, ASC weight falls to 0.814 Rule tracked on Rule tracker Open →
DEA telemedicine prescribing rule remains under White House review Rule tracked on Rule tracker Open →
Surgery Partners raises HealthSpan merger to $25 per share Deal tracked on Deal sheet Open →
CMS extends hospice and home health enrollment freeze, lets incumbents add locations Rule tracked on Rule tracker Open →
Get the next issue Free, daily